Neuroscience

Peripheral neurotoxicity of hepatitis C virus interferon therapy evaluated

Published in Hepatitis Weekly, November 6th, 2006

In a recent publication, researchers in Italy reported on the peripheral neurotoxicity of pegylated interferon alpha in the treatment of hepatitis C virus (HCV).

C. Briani and colleagues, University of Padua, wrote that the study was done "to assess whether pegylated interferon alpha (PEG-IFN alpha) may induce peripheral neuropathy or antibodies to peripheral nerve antigens in patients with hepatitis C virus (HCV) infection."

"We studied 52 patients with HCV (38 men, 14 women; mean age 44.6±10.6 years) treated with IFN alpha. Before therapy (T-0), patients underwent quantitative viral RNA determination, HCV genotype analysis, and neurologic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2006-11-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry